This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wan, X. Articles by Helman, L. J. Search for Related Content PubMed Articles by Wan, X. Articles by Helman, L. J.

Sarcomas: Sarcoma Research Series

The Biology Behind mTOR Inhibition in Sarcoma

Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Key Words. mTOR • Rapamycin • Sarcoma • Clinical trial

Correspondence: Lee J. Helman, M.D., Molecular Oncology Section, Pediatric Oncology Branch, Building 10, Room CRC-1W-3816, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1928, USA. Telephone:301-496-4257; Fax:301-451-7010; e-mail: helmanl{at}nih.gov

Received May 4, 2007; accepted for publication May 8, 2007.

Dysregulation of the mammalian target of rapamycin (mTOR) pathway has been found in many human tumors and implicated in the promotion of cancer cell growth and survival. Hence, the mTOR pathway is considered an important target for anticancer drug development. Currently, the mTOR inhibitor rapamycin and its derivatives CCI-779, RAD001, and AP23573 are being evaluated in cancer clinical trials. To date, clinical results have shown good tolerability of treatment with mTOR inhibitors in most reports and varying effectiveness of mTOR inhibitors in a variety of tumors in a subset of patients. For the targeted treatment of sarcomas, AP23573 has shown promising clinical efficacy and low toxicity profiles in patients. Further studies should define the optimal dose/schedule, patient selection, and combination strategies with other biological agents, especially those targeting signaling pathways crucial for cell survival.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				S. Stacchiotti, A. Marrari, E. Tamborini, E. Palassini, E. Virdis, A. Messina, F. Crippa, C. Morosi, A. Gronchi, S. Pilotti, et al. Response to imatinib plus sirolimus in advanced chordoma Ann. Onc., November 1, 2009; 20(11): 1886 - 1894. [Abstract] [Full Text] [PDF]

				P. A. OLIVEIRA, R. ARANTES-RODRIGUES, C. SOUSA-DINIZ, A. COLACO, L. LOURENCO, L. FELIPE. DE LA CRUZ P., V. M. DA SILVA, J. AFONSO, C. LOPES, and L. SANTOS The Effects of Sirolimus on Urothelial Lesions Chemically Induced in ICR Mice by BBN Anticancer Res, August 1, 2009; 29(8): 3221 - 3226. [Abstract] [Full Text] [PDF]

				J. SCHWAB, C. ANTONESCU, P. BOLAND, J. HEALEY, A. ROSENBERG, P. NIELSEN, J. IAFRATE, T. DELANEY, S. YOON, E. CHOY, et al. Combination of PI3K/mTOR Inhibition Demonstrates Efficacy in Human Chordoma Anticancer Res, June 1, 2009; 29(6): 1867 - 1871. [Abstract] [Full Text] [PDF]

				C. Y. Zou, K. D. Smith, Q.-S. Zhu, J. Liu, I. E. McCutcheon, J. M. Slopis, F. Meric-Bernstam, Z. Peng, W. G. Bornmann, G. B. Mills, et al. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor Mol. Cancer Ther., May 1, 2009; 8(5): 1157 - 1168. [Abstract] [Full Text] [PDF]

				C. Gridelli, P. Maione, and A. Rossi The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer Oncologist, February 1, 2008; 13(2): 139 - 147. [Abstract] [Full Text] [PDF]